Core Points - Rosen Law Firm is reminding investors who purchased Marex Group plc securities between May 16, 2024, and August 5, 2025, of the December 8, 2025, lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Marex securities during the specified Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by December 8, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Case Allegations - The lawsuit alleges that during the Class Period, Marex made materially false and misleading statements, including selling over-the-counter financial instruments to itself and inconsistencies in financial statements [5]. - It is claimed that Marex's financial statements could not be relied upon, and positive statements about the company's business were materially misleading [5].

Core Viewpoint - Rosen Law Firm is reminding purchasers of MoonLake Immunotherapeutics common stock of the upcoming lead plaintiff deadline for a class action lawsuit related to misleading statements made by the company during the class period from March 10, 2024, to September 29, 2025 [1]. Group 1: Class Action Details - Investors who purchased MoonLake common stock during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors can submit their information through the provided link or contact the law firm directly [3][6]. - A lead plaintiff must file a motion with the court by December 15, 2025, to represent other class members in the litigation [3]. Group 2: Legal Representation - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in recovering significant amounts for investors [4]. - The firm has been recognized for its achievements in securities class action settlements, including being ranked No. 1 for the number of settlements in 2017 and recovering over $438 million for investors in 2019 [4]. Group 3: Case Allegations - The complaint alleges that during the class period, MoonLake made false and misleading statements regarding the efficacy of its product SLK compared to traditional monoclonal antibodies, leading to investor damages when the truth was revealed [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against MoonLake Immunotherapeutics due to allegations of misleading statements and failure to disclose material facts regarding its product SLK, which led to significant stock price decline [2][5][6]. Group 1: Legal Investigation - Faruqi & Faruqi, LLP is encouraging investors who suffered losses in MoonLake to discuss their legal options, particularly those who acquired securities between March 10, 2024, and September 29, 2025 [1][2]. - A federal securities class action has been filed against MoonLake, with a deadline of December 15, 2025, for investors to seek the role of lead plaintiff [2][8]. Group 2: Allegations Against MoonLake - The complaint alleges that MoonLake and its executives violated federal securities laws by making false and misleading statements about the efficacy of SLK compared to BIMZELX, including claims about molecular targets and clinical benefits [5]. - Specific allegations include that SLK's distinct Nanobody structure does not provide superior clinical benefits over traditional monoclonal antibodies and that its supposed increased tissue penetration does not translate to clinical efficacy [5]. Group 3: Stock Price Impact - Following the announcement of disappointing results from the Phase 3 VELA program, MoonLake's stock price fell by $55.75 per share, or 89.9%, closing at $6.24 on September 29, 2025 [6][7].

Core Viewpoint - A lawsuit has been filed against MoonLake Immunotherapeutics and its senior executives for potential violations of federal securities laws, following disappointing results from its Phase 3 VELA trials for sonelokimab [2][4][5]. Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases [5]. - The company conducted Phase 3 VELA trials for sonelokimab, an investigational therapeutic for moderate to severe hidradenitis suppurativa [5]. Allegations and Claims - The lawsuit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, alleging that MoonLake misrepresented its clinical data and the benefits of its Nanobody structure compared to traditional monoclonal antibody treatments [4][6][7]. - The complaint suggests that the company's claims about "strong clinical data" and differentiation from competitors were misleading [6][7]. Stock Performance - Following the announcement of disappointing results from the VELA trials on September 28, 2025, MoonLake's stock price plummeted nearly 90%, from $61.99 per share to $6.24 per share [8].

Accessibility StatementSkip Navigation BENSALEM, Pa., Nov. 21, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Inspire Medical Systems, Inc. ("Inspire" or the "Company") (NYSE: INSP) 21% more press release views with Request a Demo Also from this source IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN INSPIRE MEDICAL SYSTEMS, INC. (INSP), CONTACT THE LAW OFFICES OF HOWARD G. SMIT ...

Core Viewpoint - MoonLake Immunotherapeutics has faced a significant decline in share price, dropping nearly 90% due to disappointing Phase 3 trial results for its drug candidate sonelokimab (SLK) [1][5]. Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing sonelokimab (SLK) for treating moderate to severe hidradenitis suppurativa (HS), a chronic inflammatory skin disease [3]. Legal Issues - A securities fraud class action lawsuit has been filed against MoonLake in the U.S. District Court for the Southern District of New York, alleging that the company and certain executives made materially false and misleading statements regarding SLK's clinical prospects [2][4]. - The class period for the lawsuit is from March 10, 2024, to September 29, 2025, with a lead plaintiff deadline set for December 15, 2025 [2]. Trial Results and Market Reaction - The VELA Phase 3 trials for SLK reported disappointing results, with one trial failing to meet its primary endpoint and the efficacy results from the successful trial being significantly lower than those of the competitor drug BIMZELX [4][5]. - Following the announcement of the trial results, MoonLake's stock price fell from $61.99 to $6.24, a decrease of $55.75 per share, which analysts described as a "disastrous result" [5]. Allegations of Misleading Information - The lawsuit claims that MoonLake misled investors by exaggerating SLK's advantages over competitors, particularly its unique "Nanobody" structure, which was suggested to provide superior efficacy compared to traditional monoclonal antibodies [4][6]. - Plaintiffs argue that the company's promotion of SLK as a potential "gold standard" treatment was misleading and contributed to an artificial inflation of the stock price during the class period [6].

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages MoonLake Immunotherapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - MLTXNovember 21, 2025 2:16 PM EST | Source: The Rosen Law Firm PANew York, New York--(Newsfile Corp. - November 21, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the "Class Pe ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against MoonLake (NASDAQ: MLTX) due to allegations of false and misleading statements regarding its product SLK, which failed to demonstrate competitive efficacy compared to BIMZELX, leading to a significant drop in stock price [1][3][4]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses in MoonLake between March 10, 2024, and September 29, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against MoonLake, with a deadline of December 15, 2025, for investors to seek the role of lead plaintiff [1][5]. Group 2: Allegations Against MoonLake - The complaint alleges that MoonLake and its executives violated federal securities laws by making false statements and failing to disclose material facts about the differences between Nanobodies and monoclonal antibodies [3]. - Specific allegations include that SLK and BIMZELX share the same molecular targets, and that SLK's structure does not provide superior clinical benefits or efficacy [3]. Group 3: Stock Price Impact - Following the announcement of the Phase 3 VELA program results, MoonLake's stock price fell by $55.75 per share, or 89.9%, closing at $6.24 on September 29, 2025 [4].

Accessibility StatementSkip Navigation CONTACT:Levi & Korsinsky, LLP Joseph E. Levi, Esq.Ed Korsinsky, Esq.33 Whitehall Street, 27th FloorNew York, NY 10004[email protected] Tel: (212) 363-7500Fax: (212) 363-7171www.zlk.com SOURCE Levi & Korsinsky, LLP CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of MoonLake investors who were adversely affected by alleged securities fraud between March 10, 2024 and September 29, 2025. Follow the link below to get more information and be contacted by a ...

Core Viewpoint - aTyr Pharma, Inc. is facing a class action securities lawsuit due to alleged securities fraud related to misleading statements about the efficacy of its drug Efzofitimod, which led to significant stock price decline after the truth was revealed [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover losses for aTyr investors affected by alleged securities fraud between November 7, 2024, and September 12, 2025 [1]. - Defendants allegedly provided positive statements while concealing adverse facts about Efzofitimod's efficacy, particularly its ability to allow patients to taper steroid usage [2]. - The truth emerged on September 15, 2025, when aTyr announced that the EFZO-FIT study did not meet its primary endpoint, leading to a drastic stock price drop from $6.03 to $1.02, a decline of 83.2% in one day [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant timeframe have until December 8, 2025, to request to be appointed as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the U.S. [4].